Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most clinical and administration-related claims are supported by the provided Ventolin HFA label excerpts (indications, mechanism, and route; metered-dose inhaler/administration by inhalation; exercise-induced prevention). Several safety/dosing/administration details are either unsupported by the provided excerpts or include claims that may be incomplete or potentially inconsistent with label cautions (notably the 'rapid relief' framing and the specific 'common side effects' list; also missing label-specific administration technique elements).
Category Scores
Accurate Statements
Ventolin HFA contains albuterol sulfate as its active ingredient.
Description (11): 'The active component of VENTOLIN HFA is albuterol sulfate, USP...'.
Albuterol sulfate is a bronchodilator.
Description (11): '... relatively selective beta2-adrenergic bronchodilator.'
Albuterol sulfate works by relaxing muscles in the airways to improve airflow to the lungs.
Mechanism of Action (12.1): 'Activation of beta2-adrenergic receptors on airway smooth muscle... resulting in relaxation. Albuterol relaxes the smooth muscles of all airways...'.
Ventolin HFA is a metered-dose inhaler.
Dosage Forms and Strengths (3): '... pressurized metered-dose aerosol canister...'.
Ventolin HFA is used to treat bronchospasm in patients with reversible obstructive airway disease.
Indications (1.1): 'indicated for the treatment or prevention of bronchospasm ... with reversible obstructive airway disease.'
Ventolin HFA is used to prevent bronchospasm in patients with reversible obstructive airway disease.
Indications (1.1): 'treatment or prevention of bronchospasm ... with reversible obstructive airway disease.'
Ventolin HFA is used to prevent exercise-induced bronchospasm.
Indications (1.2): 'indicated for the prevention of exercise-induced bronchospasm...'.
Ventolin HFA delivers albuterol sulfate directly into the lungs.
Indications/Dosage Administration (2.3): 'VENTOLIN HFA should be administered by the orally inhaled route only.'
Ventolin HFA is administered by inhalation.
Dosage and Administration (2.3): '... administered by the orally inhaled route only.'
Proper technique is essential to ensure the medication reaches the lungs effectively.
Administration Information (2.3): 'Priming VENTOLIN HFA is essential...' and instructions intended to ensure appropriate content/dosing.
Unsupported Statements
Ventolin HFA provides rapid relief from breathing difficulties.
No label excerpt provided states or characterizes 'rapid relief' or 'breathing difficulties' in that phrasing.
Common side effects associated with Ventolin HFA include nervousness.
The provided adverse reaction excerpts list cases (postmarketing/clinical trials description) but do not enumerate 'nervousness' as a common side effect.
Common side effects associated with Ventolin HFA include tremor.
Not supported by the provided adverse reaction excerpts.
Common side effects associated with Ventolin HFA include headache.
Not supported by the provided adverse reaction excerpts.
Common side effects associated with Ventolin HFA include nausea.
Not supported by the provided adverse reaction excerpts.
Common side effects associated with Ventolin HFA include dizziness.
Not supported by the provided adverse reaction excerpts.
Common side effects associated with Ventolin HFA include throat irritation.
Hoarseness is mentioned postmarketing (6.2), but the excerpt does not support 'throat irritation' nor that it is 'common.'
A Ventolin HFA savings card can help eligible patients reduce their out-of-pocket costs for the prescription inhaler.
No prescribing information excerpt provided addresses savings cards, manufacturer programs, eligibility, or pharmacy discount mechanics.
Savings programs are typically offered by the drug manufacturer.
Not addressed in provided label excerpts.
Savings cards apply a discount directly at the pharmacy point of sale.
Not addressed in provided label excerpts.
Some savings card programs may have monthly or annual limits on the savings available.
Not addressed in provided label excerpts.
Eligibility for Ventolin HFA savings cards typically depends on insurance status and income level.
Not addressed in provided label excerpts.
Ventolin HFA savings programs are generally intended for commercially insured patients.
Not addressed in provided label excerpts.
Ventolin HFA savings cards may not be available to those with government-funded insurance like Medicare or Medicaid.
Not addressed in provided label excerpts.
Contradictions
Important Omissions
Age restriction (patients aged 4 years and older) for bronchospasm and exercise-induced bronchospasm indications.
Importance:
Moderate
Dose and maximum dosing cautions (e.g., 'More frequent administration or a greater number of inhalations is not recommended' and 'Do Not Exceed Recommended Dose').
Importance:
Moderate
Key administration technique details required by the label (priming specifics; wash/air-dry actuator weekly; avoid spraying in eyes).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported 'common side effects' and missing label cautions (dose exceeding, paradoxical bronchospasm, deterioration of asthma) reduce alignment with safety information; however, core indications and administration route are mostly consistent with the supplied excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Unsupported claims: 'common side effects' list and savings-card program details are not supported by the provided prescribing information excerpts.
Suggested Improvement
Restrict content to label-supported statements from the provided excerpts (indications including age, administration/priming and maintenance instructions, and label warnings/precautions). Remove savings-card and enumerated 'common side effects' claims unless supported by the provided label text.